View in EDS

IA-0130, a novel 3-(1,3-diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL-6/gp130/STAT3 signalling.

Saved in:
Bibliographic Details
Title: IA-0130, a novel 3-(1,3-diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL-6/gp130/STAT3 signalling.
Authors: Park SA; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea., Kim HJ; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea., Kim LK; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea., Lee HR; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea., Jung BK; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea., Kim JH; College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea., Kim MJ; Research Institute, ILAb Co., Ltd., Seongnam, South Korea., Oh TG; Research Institute, ILAb Co., Ltd., Seongnam, South Korea., Kang HE; College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea., Shin KJ; College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea., Seo JH; Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea., Heo TH; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.
Source: British journal of pharmacology [Br J Pharmacol] 2025 Nov; Vol. 182 (22), pp. 5670-5689. Date of Electronic Publication: 2025 Jul 28.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40722241
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: IA-0130, a novel 3-(1,3-diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL-6/gp130/STAT3 signalling.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Park+SA%22">Park SA</searchLink>; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+HJ%22">Kim HJ</searchLink>; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+LK%22">Kim LK</searchLink>; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Lee+HR%22">Lee HR</searchLink>; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Jung+BK%22">Jung BK</searchLink>; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+JH%22">Kim JH</searchLink>; College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+MJ%22">Kim MJ</searchLink>; Research Institute, ILAb Co., Ltd., Seongnam, South Korea.<br /><searchLink fieldCode="AU" term="%22Oh+TG%22">Oh TG</searchLink>; Research Institute, ILAb Co., Ltd., Seongnam, South Korea.<br /><searchLink fieldCode="AU" term="%22Kang+HE%22">Kang HE</searchLink>; College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Shin+KJ%22">Shin KJ</searchLink>; College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Seo+JH%22">Seo JH</searchLink>; Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Heo+TH%22">Heo TH</searchLink>; Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227502536%22">British journal of pharmacology</searchLink> [Br J Pharmacol] 2025 Nov; Vol. 182 (22), pp. 5670-5689. <i>Date of Electronic Publication: </i>2025 Jul 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>7502536 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5381 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071188%22">00071188 </searchLink><i>NLM ISO Abbreviation: </i>Br J Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40722241
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bph.70142
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5670
    Titles:
      – TitleFull: IA-0130, a novel 3-(1,3-diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL-6/gp130/STAT3 signalling.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Park SA
      – PersonEntity:
          Name:
            NameFull: Kim HJ
      – PersonEntity:
          Name:
            NameFull: Kim LK
      – PersonEntity:
          Name:
            NameFull: Lee HR
      – PersonEntity:
          Name:
            NameFull: Jung BK
      – PersonEntity:
          Name:
            NameFull: Kim JH
      – PersonEntity:
          Name:
            NameFull: Kim MJ
      – PersonEntity:
          Name:
            NameFull: Oh TG
      – PersonEntity:
          Name:
            NameFull: Kang HE
      – PersonEntity:
          Name:
            NameFull: Shin KJ
      – PersonEntity:
          Name:
            NameFull: Seo JH
      – PersonEntity:
          Name:
            NameFull: Heo TH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1476-5381
          Numbering:
            – Type: volume
              Value: 182
            – Type: issue
              Value: 22
          Titles:
            – TitleFull: British journal of pharmacology
              Type: main
ResultId 1